Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYPLA1 | O75608 | 1/20 | 0.46 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407160 | 0.75 | KDM4E (0.53) | KDM4E | |
| SCHEMBL2411647 | 0.74 | LYPLA1 (0.47) | LYPLA1LYPLA2MAPTCHRNB2CHRNA4 | |
| SCHEMBL2411606 | 0.74 | LYPLA1 (0.47) | LYPLA1LYPLA2MAPTCHRNB2CHRNA4 | |
| SCHEMBL12266378 | 0.72 | LYPLA1 (0.59) | LYPLA1LYPLA2KDM4ESMN1; SMN2 | |
| SCHEMBL21444471 | 0.71 | MAPT (0.60) | MAPTCHRNB2CHRNA4KDM4ESMN1; SMN2 | |
| SCHEMBL2407885 | 0.70 | LYPLA1 (0.54) | LYPLA1LYPLA2KDM4E | |
| SCHEMBL12270761 | 0.68 | LYPLA1 (0.48) | LYPLA1LYPLA2MAPTCHRNB2CHRNA4 | |
| SCHEMBL12266325 | 0.68 | LYPLA1 (0.50) | LYPLA1LYPLA2TAAR1KDM4E | |
| SCHEMBL13476010 | 0.67 | LYPLA1 (0.61) | LYPLA1LYPLA2CHRNB2CHRNA4KDM4E | |
| SCHEMBL12266287 | 0.67 | LYPLA1 (0.70) | LYPLA1LYPLA2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| WO-2010018837-A2 | PROTEIN CROSS-LINKING INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018836-A2 | POLYGLUTAMINE AGGREGATION INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | LYPLA1 1153/4885LYPLA2 1988/4885MAPT 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.